DOCSLIB.ORG

As on March 31, 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
As on March 31, 2012 UNAUDITED HALF - YEARLY PORTFOLIO STATEMENT OF THE SCHEMES OF FRANKLIN TEMPLETON MUTUAL FUND AS ON MARCH 31, 2012 FRANKLIN TEMPLETON FIXED TENURE FUND - SERIES IX - PLAN B FRANKLIN TEMPLETON FIXED TENURE FUND - SERIES X - PLAN C (CONTD.) FRANKLIN TEMPLETON FIXED TENURE FUND - SERIES XII - PLAN A (CONTD.) Company Name Industry Classification Quantity Market Value % to Net Company Name Industry Classification Quantity Market Value % to Net Company Name Industry Classification Quantity Market Value % to Net (` in Lakhs) Assets (` in Lakhs) Assets (` in Lakhs) Assets Debt Instruments Rating Indusind Bank Ltd Banks 81,290 260.78 0.73 Equity & Equity Related (a) Listed / awaiting listing on Stock Exchanges Marico Ltd Consumer Non Durables 133,750 233.39 0.66 (a) Listed/Awaiting listing on Stock Exchanges Non - Traded / Thinly Traded Scrips Infosys Ltd Software 5,397 154.62 2.53 Mahindra & Mahindra Ltd Auto 29,362 204.62 0.58 Power Finance Corp Ltd CRISIL AAA 30 297.69 12.03 ICICI Bank Ltd Banks 13,017 115.49 1.89 Power Grid Corp Of India Power 168,927 182.27 0.51 Grasim Industries Ltd Cement 4,000 105.17 1.72 Tata Motors Ltd CRISIL AAA(SO) 25 294.41 11.89 Oil & Natural Gas Corp Ltd Oil 67,200 179.63 0.51 Cummins India Ltd Industrial Products 19,000 94.40 1.55 National Housing Bank CRISIL AAA 30 292.21 11.81 Eicher Motors Ltd Auto 8,931 177.12 0.50 Bharti Airtel Ltd Telecom - Services 27,926 94.04 1.54 Export-Import Bank Of India CRISIL AAA 27 273.05 11.03 Coal India Ltd Minerals/Mining 42,999 147.53 0.42 HDFC Bank Ltd Banks 17,180 89.34 1.46 Power Grid Corp Of India CRISIL AAA 20 248.12 10.02 IPCA Laboratories Ltd Pharmaceuticals 42,000 140.70 0.40 Kotak Mahindra Bank Ltd Banks 13,838 75.06 1.23 Indian Railway Finance Corp CRISIL AAA 18 179.16 7.24 Cadila Healthcare Pharmaceuticals 16,000 121.62 0.34 Reliance Industries Ltd Petroleum Products 9,901 74.08 1.21 Dr Reddy'S Laboratories Ltd ICRA AA+ 3,030 0.15 0.01 Dr Reddy'S Laboratories Ltd Pharmaceuticals 6,475 113.87 0.32 Indusind Bank Ltd Banks 20,716 66.46 1.09 Total 1,584.79 64.03 Oracle Financial Services Software Ltd Software 4,029 105.57 0.30 Marico Ltd Consumer Non Durables 35,000 61.08 1.00 Wipro Ltd Software 23,721 104.14 0.29 Mahindra & Mahindra Ltd Auto 7,547 52.60 0.86 Totals 2,295.34 92.74 Pidilite Industries Ltd Chemicals 47,992 85.21 0.24 Power Grid Corp Of India Power 43,375 46.80 0.77 Hindalco Industries Ltd Non - Ferrous Metals 64,069 82.94 0.23 Call, Cash & Other Assets 179.91 7.26 Oil & Natural Gas Corp Ltd Oil 16,812 44.94 0.74 India Cements Ltd Cement 73,506 81.81 0.23 Eicher Motors Ltd Auto 2,271 45.04 0.74 State Bank Of India Banks 3,711 77.75 0.22 Coal India Ltd Minerals/Mining 10,942 37.54 0.61 Net Assets 2,475.25 100.00 Dabur India Ltd Consumer Non Durables 73,000 77.67 0.22 IPCA Laboratories Ltd Pharmaceuticals 10,900 36.52 0.60 Note: Idea Cellular Ltd Telecom - Services 74,445 73.59 0.21 Cadila Healthcare Pharmaceuticals 4,100 31.16 0.51 Axis Bank Ltd Banks 6,400 73.34 0.21 Dr Reddy'S Laboratories Ltd Pharmaceuticals 1,641 28.86 0.47 a) NAV at the beginning and at the end of the Half-year ended March 31, 2012 Asian Paints Ltd Consumer Non Durables 2,250 72.85 0.20 Oracle Financial Services Software Ltd Software 1,023 26.80 0.44 NAV as on 30-Sep-2011 Orient Paper & Industries Ltd Cement 118,026 69.87 0.20 Wipro Ltd Software 5,825 25.57 0.42 ` Dividend Option ( ) 11.7332 Steel Authority Of India Ltd Ferrous Metals 74,264 69.85 0.20 Pidilite Industries Ltd Chemicals 12,426 22.06 0.36 Growth Option (`) 12.8650 Hindalco Industries Ltd Non - Ferrous Metals 16,731 21.66 0.35 Crompton Greaves Limited Industrial Capital Goods 49,641 68.58 0.19 India Cements Ltd Cement 19,207 21.38 0.35 NAV as on 31-Mar-2012 Voltas Limited Construction Project 61,000 68.35 0.19 ` Dabur India Ltd Consumer Non Durables 19,000 20.22 0.33 Dividend Option ( )# 11.4382 Tata Steel Ltd Ferrous Metals 14,300 67.27 0.19 ` State Bank Of India Banks 924 19.36 0.32 Growth Option ( )# 13.3810 ICRA Ltd Finance 5,912 66.26 0.19 Idea Cellular Ltd Telecom - Services 19,180 18.96 0.31 b) Dividends declared during the Half - year ended March 31, 2012: Bank Of Baroda Banks 8,000 63.49 0.18 Orient Paper & Industries Ltd Cement 31,424 18.60 0.30 NTPC Ltd Power 38,558 62.73 0.18 Dividend per unit Axis Bank Ltd Banks 1,600 18.33 0.30 Jagran Prakashan Ltd Media & Entertainment 56,657 57.00 0.16 Plan Name Steel Authority Of India Ltd Ferrous Metals 19,291 18.14 0.30 Indian Oil Corp Ltd Petroleum Products 20,000 52.52 0.15 Individuals/HUF Others Asian Paints Ltd Consumer Non Durables 550 17.81 0.29 NHPC Ltd Power 248,000 48.73 0.14 Crompton Greaves Limited Industrial Capital Goods 12,822 17.71 0.29 Dividend Option 0.6607 0.5663 Glaxosmithkline Pharmaceuticals Ltd Pharmaceuticals 1,800 41.23 0.12 Voltas Limited Construction Project 15,700 17.59 0.29 TV18 Brodcast Ltd Media & Entertainment 144,096 39.84 0.11 Tata Steel Ltd Ferrous Metals 3,700 17.40 0.28 c) Average Maturity as on March 31, 2012 1.04 Years Gujarat Pipavav Port Ltd Transportation 60,000 35.28 0.10 ICRA Ltd Finance 1,478 16.56 0.27 JK Lakshmi Cement Limited Cement 53,000 34.56 0.10 NTPC Ltd Power 9,768 15.89 0.26 FRANKLIN TEMPLETON FIXED TENURE FUND - SERIES X - PLAN D Gujarat Mineral Dev Corp Ltd Minerals/Mining 18,000 32.79 0.09 Bank Of Baroda Banks 2,000 15.87 0.26 TVS Motor Company Limited Auto 59,000 24.19 0.07 Jagran Prakashan Ltd Media & Entertainment 14,689 14.78 0.24 Company Name Industry Classification Quantity Market Value % to Net ` Total 6,529.11 18.41 Indian Oil Corp Ltd Petroleum Products 5,300 13.92 0.23 (in Lakhs) Assets NHPC Ltd Power 66,000 12.97 0.21 TV18 Brodcast Ltd Media & Entertainment 38,356 10.61 0.17 Equity & Equity Related Debt Instruments Rating Glaxosmithkline Pharmaceuticals Ltd Pharmaceuticals 450 10.31 0.17 (a) Listed/Awaiting listing on Stock Exchanges (a) Listed / awaiting listing on Stock Exchanges Gujarat Pipavav Port Ltd Transportation 15,000 8.82 0.14 Infosys Ltd Software 760 21.77 2.57 Non - Traded / Thinly Traded Scrips Gujarat Mineral Dev Corp Ltd Minerals/Mining 4,800 8.74 0.14 ICICI Bank Ltd Banks 1,856 16.47 1.95 Bharat Petroleum Corporation Ltd CRISIL AAA 470 4,630.42 13.03 JK Lakshmi Cement Limited Cement 13,000 8.49 0.14 Cummins India Ltd Industrial Products 2,961 14.71 1.74 Rural Electrification Corp Ltd CRISIL AAA 465 4,587.99 12.91 TVS Motor Company Limited Auto 15,000 6.16 0.10 Bharti Airtel Ltd Telecom - Services 3,903 13.14 1.55 Housing Development Finance Corp CRISIL AAA 350 4,208.55 11.84 Total 1,697.91 27.78 HDFC Bank Ltd Banks 2,425 12.61 1.49 Indian Railway Finance Corp CRISIL AAA 300 2,993.24 8.42 Kotak Mahindra Bank Ltd Banks 1,988 10.78 1.27 NABARD CRISIL AAA 300 2,981.42 8.39 Debt Instruments Rating Reliance Industries Ltd Petroleum Products 1,337 10.00 1.18 Power Finance Corp Ltd CRISIL AAA 300 2,960.55 8.33 (a) Listed / awaiting listing on Stock Exchanges Indusind Bank Ltd Banks 2,894 9.28 1.10 LIC Housing Finance Ltd CRISIL AAA 290 2,864.22 8.06 Non - Traded / Thinly Traded Scrips Marico Ltd Consumer Non Durables 4,794 8.37 0.99 Ultra Tech Cement Ltd CRISIL AAA 9 890.84 2.51 Tata Motors Ltd CRISIL AAA(SO) 75 883.24 14.46 Mahindra & Mahindra Ltd Auto 1,046 7.29 0.86 Indian Oil Corp Ltd CRISIL AAA 50 493.90 1.39 Power Finance Corp Ltd CRISIL AAA 70 694.61 11.37 Power Grid Corp Of India Power 6,151 6.64 0.78 Dr Reddy'S Laboratories Ltd ICRA AA+ 26,250 1.30 0.00* Indian Railway Finance Corp CRISIL AAA 68 676.84 11.08 Oil & Natural Gas Corp Ltd Oil 2,436 6.51 0.77 Total 26,612.43 74.88 Power Grid Corp Of India CRISIL AAA 50 621.11 10.17 Eicher Motors Ltd Auto 301 5.97 0.71 NABARD CRISIL AAA 60 585.40 9.58 Grasim Industries Ltd Cement 215 5.65 0.67 Totals 33,141.54 93.29 Rural Electrification Corp Ltd CRISIL AAA 50 496.60 8.13 Coal India Ltd Minerals/Mining 1,534 5.26 0.62 Dr Reddy'S Laboratories Ltd ICRA AA+ 6,846 0.34 0.01 Call, Cash & Other Assets 2,396.46 6.71 IPCA Laboratories Ltd Pharmaceuticals 1,500 5.03 0.59 Total 3,958.14 64.80 Cadila Healthcare Pharmaceuticals 600 4.56 0.54 Net Assets 35,538.00 100.00 Dr Reddy'S Laboratories Ltd Pharmaceuticals 257 4.52 0.53 Totals 5,656.05 92.58 Wipro Ltd Software 804 3.53 0.42 Asian Paints Ltd Consumer Non Durables 100 3.24 0.38 *Less than 0.01% Call, Cash & Other Assets 451.76 7.42 Hindalco Industries Ltd Non - Ferrous Metals 2,395 3.10 0.37 Note: Pidilite Industries Ltd Chemicals 1,728 3.07 0.36 Net Assets 6,107.81 100.00 a) NAV at the beginning and at the end of the Half-year ended March 31, 2012 Oracle Financial Services Software Ltd Software 116 3.04 0.36 Note: India Cements Ltd Cement 2,646 2.94 0.35 NAV as on 30-Sep-2011 Axis Bank Ltd Banks 250 2.86 0.34 Dividend Option (`) 10.6949 a) NAV at the beginning and at the end of the Half-year ended March 31, 2012 Dabur India Ltd Consumer Non Durables 2,600 2.77 0.33 Growth Option (`) 10.8978 NAV as on 30-Sep-2011 State Bank Of India Banks 127 2.66 0.31 Dividend Option (`) 11.4595 Idea Cellular Ltd Telecom - Services 2,681 2.65 0.31 NAV as on 31-Mar-2012 ` Growth Option (`) 12.3806 Steel Authority Of India Ltd Ferrous Metals 2,780 2.61 0.31 Dividend Option ( )# 10.7356 ` Tata Steel Ltd Ferrous Metals 550 2.59 0.31 Growth Option ( )# 11.3083 NAV as on 31-Mar-2012 Crompton Greaves Limited Industrial Capital Goods 1,724 2.38 0.28 Dividend Option (`)# 11.2726 b) Dividends declared during the Half - year ended March 31, 2012: Growth Option (`)# 12.8961 Bank Of Baroda Banks 300 2.38 0.28 Voltas Limited Construction Project 2,100 2.35 0.28 Dividend per unit b) Dividends declared during the
Load more

Recommended publications
  • Replacements in Indices
    Date: February 21, 2018 PRESS RELEASE Replacements in Indices The Index Maintenance Sub-Committee (IMSC) has decided to make the following replacement of stocks in various indices as part of its periodic review. These changes shall become effective from April 02, 2018 (close of March 28, 2018). 1) NIFTY 50 The following companies are being excluded: Sr. No. Company Name Symbol 1 Ambuja Cements Ltd. AMBUJACEM 2 Aurobindo Pharma Ltd. AUROPHARMA 3 Bosch Ltd. BOSCHLTD The following companies are being included: Sr. No. Company Name Symbol 1 Bajaj Finserv Ltd. BAJAJFINSV 2 Grasim Industries Ltd. GRASIM 3 Titan Company Ltd. TITAN The above replacements will also be applicable to NIFTY50 Equal Weight Index. 2) NIFTY Next 50 The following companies are being excluded: Sr. No. Company Name Symbol 1 Bajaj Finserv Ltd. BAJAJFINSV 2 GlaxoSmithkline Consumer Healthcare Ltd. GSKCONS 3 Glaxosmithkline Pharmaceuticals Ltd. GLAXO 4 Glenmark Pharmaceuticals Ltd. GLENMARK 5 Tata Power Co. Ltd. TATAPOWER 6 Titan Company Ltd. TITAN 7 Torrent Pharmaceuticals Ltd. TORNTPHARM The following companies are being included: Sr. No. Company Name Symbol 1 Aditya Birla Capital Ltd. ABCAPITAL Sr. No. Company Name Symbol 2 Ambuja Cements Ltd. AMBUJACEM 3 Aurobindo Pharma Ltd. AUROPHARMA 4 Bosch Ltd. BOSCHLTD 5 General Insurance Corporation of India GICRE 6 L&T Finance Holdings Ltd. L&TFH 7 SBI Life Insurance Company Ltd. SBILIFE 3) NIFTY 500 The following companies are being excluded: Sr. No. Company Name Symbol 1 Adani Enterprises Ltd. ADANIENT 2 Ahluwalia Contracts (India) Ltd. AHLUCONT 3 Apar Industries Ltd. APARINDS 4 AstraZenca Pharma India Ltd. ASTRAZEN 5 Corporation Bank CORPBANK 6 Dalmia Bharat Ltd.
    [Show full text]
  • 50 KW Offer Solar Copy 2
    21st Century Enviro Engineers Pvt.Ltd. Plot No. 120(10 Marla), COMPANY Industrial Area Phase II Chandigarh - 160002, India PROFILE www.21stcenturyenviro.com INTRODUCTION 21st CENTURY ENVIRO ENGINEERS PVT. LTD. is a Company dealing in the field of Environmental Engineering related activities. We are Registered Environmental Consultants of Pollution Control Board to Supply ETP’s, STP’s, APCD’s, Incinerators, Water Treatment Plants, Reverse Osmosis, Evaporators, Solid Waste Management and Rain Water Harvesting and to carry out EIA Studies . The Directors of the company are young Technocrats having versatile experience in this field. We have a back up of highly qualified and experienced technical team having versatile experience in Designing, Erection, Commissioning and Operation of different types of Effluent Treatment Plants. Our Managing Director himself is a Chemical Engineer with almost 25 Years Experience in this line and Technical Director is PhD. in Environmental Science with almost 30 Years working experience on various types of effluent treatment Technologies. Our team comprises of almost 150 people from different backgrounds e.g. Chemical, Environmental, Mechanical, Instrumentation, Civil, Accounts, Purchase, Marketing etc. We have our Marketing/ Design Office in Chandigarh and regional offices in Dhaka, Mumbai, New Delhi, Sikkim etc. and have our own testing Laboratory for Effluent/Water Testing and to study treatability of effluent on pilot scale. We have our own full-fledged manufacturing unit of Pollution Control Equipments in Village Kunjhal Baddi (HP). We also undertake annual operation and maintenance contracts and liasining services for the systems supplied by us. We are also Registered with CREST (Chandigarh Renewable Energy & Technology Promotion Society) and SECI (Solar Energy Corporation of India) for supplying Online/Offline Solar systems in Chandigarh, Himachal Pradesh, Uttarakhand, J&K, Punjab, Haryana, Delhi, Bihar etc.
    [Show full text]
  • Index Stock Update >> Marico Stock Update >> Gabriel India Stock Update >> PTC India Stock
    Visit us at www.sharekhan.com November 04, 2015 Index Stock Update >> Marico Stock Update >> Gabriel India Stock Update >> PTC India Stock Update >> Ipca Laboratories Stock Update >> Skipper Viewpoint >> Lloyd Electric & Engineering For Private Circulation only REGISTRATION DETAILS Regd Add: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos. BSE - INB/INF011073351 ; BSE- CD ; NSE - INB/ INF231073330 ; CD-INE231073330 ; MSEI - INB/INF261073333 ; CD-INE261073330 ; DP - NSDL-IN-DP-NSDL-233-2003 ; CDSL-IN-DP-CDSL-271-2004 ; PMS- INP000000662 ; Mutual Fund-ARN 20669 ; Commodity trading through Sharekhan Commodities Pvt. Ltd.: MCX-10080 ; (MCX/TCM/CORP/0425) ; NCDEX- 00132 ; (NCDEX/TCM/CORP/0142) ; NCDEX SPOT-NCDEXSPOT/116/CO/11/20626 ; For any complaints email at [email protected] ; Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and Do’s & Don’ts by MCX & NCDEX and the T & C on www.sharekhan.com before investing. investor’s eye stock update Marico Reco: Buy Stock Update Enhanced focus to improve volume growth; maintain Buy CMP: Rs399 Company details Key points Price target: Rs460 Mixed operating performance: During Q2FY2016, Marico’s revenue grew by 4% to Rs1,485.4 crore, entirely driven by a 4% volume growth (domestic business’ volume Market cap: Rs25,735 cr growth stood at 5.5%). The gross profit margin (GPM) improved by almost 500BPS to 52 week high/low: Rs466/299 49.3% on the back of ~30% decline in the copra prices and 33% decline in the prices of liquid paraffin.
    [Show full text]
  • Inner 25 India Pharma & Healthcare Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
    [Show full text]
  • Ipca Laboratories (IPCLAB)
    Ipca Laboratories (IPCLAB) CMP: | 2040 Target: | 2290 (12%) Target Period: 12 months HOLD May 31, 2021 Upbeat guidance, execution remains key Q4 revenues remained subdued growing just 3.8% YoY to | 1115 crore. Strong YoY growth of 19.7% in export formulations to | 338 crore was partly Particulars offset by API sales decline of 5.5% YoY to | 260 crore. Domestic Particular Amount formulations remained flat at | 434 crore vs. | 431 crore in Q4FY20. EBITDA Market Capitalisation | 25873 crore margins improved 484 bps YoY to 20.5% due to better gross margins and Debt (FY21) | 267 crore lower other expenditure. EBITDA grew 35.8% YoY to | 229 crore. PAT grew Cash (FY21) | 365 crore 87.5% YoY to | 161 crore (I-direct estimate: | 204 crore). Delta vis-à-vis EV | 25775 crore EBITDA was due to higher other income, lower depreciation and tax rate. 52 week H/L (|) 2456/1467 Equity capital | 25.4 crore Update Result Export formulations main catalyst for growth Face value | 2 Price performance Growth in export formulations (29% of FY21 revenues) was on the back of growth in both international generics and international branded 2500 14000 formulations. The international anti-malarial institutional business has also 12000 2000 contributed substantially to overall exports growth. US traction will take 10000 longer than earlier estimated due to USFDA import alerts for the Ratlam 1500 8000 facility that is the only API source for Silvassa and Pithampur formulations 1000 6000 plants along with Silvassa and Pithampur (Indore) plants that are specifically 4000 500 earmarked for the US business, besides third party sales.
    [Show full text]
  • Pharma Sector Report -Sept’20
    Mutual Fund: Pharma Sector Report -Sept’20 Private & confidential. Only for limited circulation. Contact us: [email protected] Executive Summary: Since the outbreak of the Coronavirus crisis, the pharma sector stepped into the spotlight. Long overdue investments have been flowing towards the sector and even pharma funds in the mutual fund industry have begun to outperform. Nevertheless, there is still a clear need for government spending in this sector. Compared to the US, which has the highest per capita spending on healthcare at $5000, India spends merely ~ $50 per capita. The current situation presents the Indian government with a perfect opportunity to increase its expenditure in this sector, to facilitate its growth and fast-track its progress. Few points about the Pharma Funds: The market capitalization of the entire pharma & healthcare industry is ~ Rs. 10 lac crs, whereas the total size of pharma funds in the mutual fund is ~Rs. 10k crs, translating to ~ 1% of the entire sector in value terms. (This excludes the pharma holdings in other categories). There are 43 pharma & healthcare companies that form part of the Top 500 companies. Out of these, pharma funds have an exposure to 36 companies. There are 11 companies in the Top 100; 11 in the Midcap space (101-250) and 14 Smallcaps (251-500). The 7 companies that do not form part of the pharma funds’ portfolios are Caplin Point Lab, Glenmark Pharma, Granules India, Piramal Enterprises, Poly Medicure, Suven Pharma and Wockhardt Ltd. Cipla Ltd., Divis Laboratories Ltd. and Dr. Reddy’s Laboratories Ltd. are the only stocks that form part of every pharma fund.
    [Show full text]
  • List of 3Rd Party Manufacturer of Pre-Qualified/Registered Firms with PPT Hospital
    List of 3rd party Manufacturer of Pre-qualified/Registered Firms with PPT Hospital SL. Name of the Parent Firm Name of the 3rd party manufacturer NO A B C 1 M/s AKUMENTIS HEALTHCARE LTD. (i) M/S Unimark Healthcare Ltd (ii) M/S Applied Communication & Controls (iii) Maxcure Nutravedics Ltd (iv) Akums Drugs & Pharmaceuticals Ltd 2 M/s ALCON LABORATORIES(INDIA)PVT.LTD (i) M/S Wintac Limited 3 M/s ABBOTT HEALTHCARE PVT. LTD. (i) Akums Drugs & Pharmaceuticals Ltd (ii) Medibios Laboratories Pvt. Ltd. (iii) Tristar Formulations Pvt. Ltd. (iv) Hetero Labs Ltd (v) M/S Aqua Vitoe Laboratories 4 M/s ABBOTT INDIA LIMITED. (i) Acme Formulation Pvt Ltd (ii) Revenbhel Healthcare Pvt. Ltd. 5 M/s CENTAUR PHARMACEUTICALS PVT. LTD. (i) M/S Pure & Cure Healthcare Pvt. Ltd. (ii) M/S The Madras Pharmaceuticals (iii) M/S Akums Drugs & Pharmaceuticals Limited 6 M/S CIPLA LIMITED (i) Akums Drugs & Pharmaceuticals Ltd (ii) BDR Pharmaceuticals International Pvt. Ltd. (iii) M/S Medispray Laboratories Pvt. Ltd. (iv) M/S Golden Cross Pharma Pvt. Ltd. (v) M/S Tirupati Medicare Limited (vi) M/S Mepromax Lifesciences PVT Ltd. (vii) M/S Virchow Biotech Private Limited (viii) Hetero Labs Ltd (ix) Pegasus Farmaco Iindia Pvt. Ltd. (x) Meditab Specialities Pvt. Ltd. 7 M/s DR. REDDYS LABORATORIES LTD (i) Bdr Pharmaceuticals Ltd (ii) Naprod Lifesciences Pvt. Ltd (iii) Hetero Labs Ltd (iv) Natco Pharma Ltd (v) Amgen Manufacturing Limited 8 M/s FOURRTS (INDIA) LABORATORIES PVT. (i) M/S Swiss Garnier Biotech (ii) M/S Sun Glow Pharmaceuticals Private Limited 9 M/s GLOBUS REMEDIES (i) Park Pharmaceuticals (ii) Baxil Pharma Pvt.
    [Show full text]
  • Weights for New Portfolio of India Small Cap Index (ISCIN) - As on March 12, 2013 S No Ticker Name ISIN SEDOL Weights 1 FB in Equity Federal Bank Ltd
    Weights for New Portfolio of India Small Cap Index (ISCIN) - As on March 12, 2013 S No Ticker Name ISIN SEDOL Weights 1 FB IN Equity Federal Bank Ltd. INE171A01011 6139845 4.00% 2 APHS IN Equity Apollo Hospitals Enterprise Ltd. INE437A01024 6273583 3.52% 3 ABNL IN Equity Aditya Birla Nuvo Ltd. INE069A01017 6100421 3.43% 4 TTCH IN Equity Tata Chemicals Ltd. INE092A01019 6101167 3.26% 5 MMFS IN Equity Mahindra & Mahindra Financial Services Ltd. INE774D01024 B8F8822 3.25% 6 TGBL IN Equity Tata Global Beverages Ltd. INE192A01025 6121488 3.09% 7 HPCL IN Equity Hindustan Petroleum Corp. Ltd. INE094A01015 6100476 2.95% 8 EXID IN Equity Exide Industries Ltd. INE302A01020 B1D3ZC9 2.86% 9 RCAPT IN Equity Reliance Capital Ltd. INE013A01015 6101082 2.44% 10 UNTP IN Equity United Phosphorus Ltd. INE628A01036 B0L0W35 2.32% 11 PLNG IN Equity Petronet LNG Ltd. INE347G01014 B00KT68 2.24% 12 AL IN Equity Ashok Leyland Ltd. INE208A01029 B01NFT1 2.20% 13 UT IN Equity Unitech Ltd. INE694A01020 B17MRV5 2.14% 14 CRG IN Equity Crompton Greaves Ltd. INE067A01029 B1B90H9 2.08% 15 OBC IN Equity Oriental Bank of Commerce INE141A01014 6121507 2.01% 16 IPCA IN Equity IPCA Laboratories Ltd. INE571A01020 6433473 1.96% 17 JUBI IN Equity Jubilant FoodWorks Ltd. INE797F01012 B3PRM66 1.94% 18 MRF IN Equity MRF Ltd. INE883A01011 6214128 1.88% 19 ALBK IN Equity Allahabad Bank INE428A01015 6708289 1.85% 20 STR IN Equity Strides Arcolab Ltd. INE939A01011 6690535 1.84% 21 DITV IN Equity Dish TV India Ltd. INE836F01026 B1RMW32 1.78% 22 JKBK IN Equity Jammu & Kashmir Bank Ltd.
    [Show full text]
  • View Annual Report
    CONTENTS CHAIRMAN’S LETTER DEAR SHAREHOLDERS FY2012 has been a good year for your Company. The key financial results were: ¥ Consolidated revenues increased by 30% to Rs. 96.7 billion in FY2012. ¥ Earnings before interest, taxes, depreciation and amortization (EBITDA)1 rose by 55% to Rs. 25.4 billion. ¥ Profit after Tax (PAT)2 grew by 45% to Rs. 15.3 billion. ¥ Diluted Earnings per Share (EPS) increased from Rs. 64.9 in FY2011 to Rs. 83.8 in FY2012. I am particularly delighted by four developments. First, your Company succeeded in yet another blockbuster generic launch in the USA under 180- days marketing exclusivity. Dr. Reddy’s launched olanzapine 20 mg tablets, the generic version of the brand Zyprexa®. Olanzapine is used to treat schizophrenia and bipolar disorder. This product has added around USD 100 million to your Company’s revenues for FY2012. Second, the biosimilars business continues along its impressive growth path. In my letter to you last year, I had discussed the critical importance of developing biosimilars in the years to come. I am happy to note that your Company’s global biosimilars business grew by 45% over last year and recorded sales of USD 26 million. Today, the biosimilars portfolio of Dr. Reddy’s constitutes (i) filgrastim, (ii) peg-filgrastim, (iii) rituximab and (iv) darbepoetin alfa, which have commercial presence in 13 countries among emerging markets. These are helping to treat patients suffering from cancer — and at prices that are significantly more affordable than the corresponding innovator drugs. Soon, I expect to see Dr. Reddy’s biosimilars entering developed markets.
    [Show full text]
  • Name: 2Nd APPCON India - ASIAN Pharma Packaging Conference Location: Mumbai-India Dates: 2Nd & 3Rdnovember 2017
    Name: 2nd APPCON India - ASIAN Pharma Packaging Conference Location: Mumbai-India Dates: 2nd & 3rdNovember 2017 For Agenda/Event Brochure, Information & Registration, Contact: Priyesh Waghmare E: [email protected] | T: +91 (0)20.6527.2803 Quote discount code: PPCi1MP20 to claim for 20% discount expiring 7th September 2017 & PPCi1MP15 to claim for 15% discount expiring 19th October 2017 The objective of the conference is to secure and optimize packaging by navigating regulatory requirements with innovative materials and technologies. http://www.acius.net/?cID=299 Key Highlights: 20+ speakers 100+ senior packaging heads from pharma companies 10 exhibitors 2-days of branding opportunities through innovative formats such as technology shootout, site visit and speaking Early Confirmed Speakers: Chief Advisor: Santanu Chowdhury, Senior General Manager, Packaging Development, Sun Pharma Barun Kumar Dey, Director & Head Packaging Development, Dr Reddy’s Laboratories Lokesh Sharma, Director-Supply Chain, Eisai Pharmaceuticals Prasad Satam, GM Packaging Research Development, Aurobindo Pharma Alpesh Shah, General Manager-Packaging, Intas Pharmaceuticals Kaushik Roy, GM – Packaging Research Development, Mylan Laboratories Pradeep Dhargalkar, Head Packaging Development, Unichem Laboratories Atul Mulay, Deputy General Manager – Packaging Development, Cadila Pharmaceuticals Ajay Bapat, Head Packaging Development, Emcure Pharmaceuticals Munindra Roy, Senior Manager Packaging Development, Gland Pharma K Ram Mohan, Senior Packaging, NATCO
    [Show full text]
  • Tata Large Cap Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata Large Cap Fund o i L g (An open-ended equity scheme predominantly investing in large cap stocks.) h Riskometer Investors understand that their principal As on 31st May 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets Primarily invests in equity and equity related instruments of large market cap companies. Equity & Equity Related Total 92298.33 96.73 Insurance Auto Sbi Life Insurance Company Ltd. 120000 1170.78 1.23 INVESTMENT OBJECTIVE Mahindra & Mahindra Ltd. 104000 840.27 0.88 ICICI Lombard General Insurance Co. Ltd. 80000 1177.52 1.23 To provide income distribution and / or medium to long Auto Ancillaries Petroleum Products term capital gains while at all times emphasising the importance of capital appreciation. However, there is no Endurance Technologies Ltd. 73000 1089.53 1.14 Reliance Industries Ltd. 336500 7269.41 7.62 assurance or guarantee that the investment objective of Banks Pharmaceuticals the Scheme will be achieved. The scheme does not ICICI Bank Ltd. 1420000 9411.05 9.86 Cipla Ltd. 203000 1927.18 2.02 assure or guarantee any returns. HDFC Bank Ltd. 520000 7882.42 8.26 Sun Pharmaceutical Industries Ltd. 250000 1670.75 1.75 DATE OF ALLOTMENT State Bank Of India 1624000 6891.44 7.22 J.B.Chemicals & Pharmaceuticals Ltd. 74000 1073.59 1.13 May 07,1998 Axis Bank Ltd.
    [Show full text]
  • Market Masala… the Flavors That Influenced the Market This Week
    Go India Advisors Weekly Newsletter Market Masala… The flavors that influenced the market this week Week 24/CY20: 6th – 12th June 2020 1 Headlines this week Go India Advisors Another Day, another Deal; Powell GDP statement; Court – interest(ed) or not Weekly Newsletter Supreme Court clarified on the case of interest charged during moratorium. The issue now is limited to interest on interest deferred during moratorium. This is significant less Jio announced 7th and 8th sale of it's equity, this time 1.16% for threatening than question of interest waiver all together. Rs5683cr to Abu Dhabi Investment Authority (ADIA) and Banking sector took a sigh of relief and so did Indian additional 0.93% to Silver Lake Partners for Rs4546cr. Totalling upto 21.06% stake for Rs97885cr. More deals in offing are market. TPG(US$1.5bn), Saudi Arabia's Public Investment Fund (PIF) (US$1.5bn). And some rumours about either Google or Microsoft coming in. US Fed in it MPC on Thursday was dovish as expected. However more than expected downbeat assessment of the economy proved little bit too much for the stock markets to handle. This triggered the worst falls in stock market since 16th March. 13-06-2020 2 Global Markets – risk off Go India Advisors US Fed downbeat assessment of the economy, too hot for market to handle Weekly Newsletter Returns % Data for year 2020; except as specified 13-06-2020 3 Indian market – rally takes a breather Go India Advisors Volatility is the name of the game Weekly Newsletter Indian Markets for Week Ending 12th June 2020 For more information: Click on the image.
    [Show full text]